Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in Grade IV Astrocytic Tumors
NCT01068782Phase 2Terminated
- Sponsor
- Exelixis, Inc.
- Start
- Apr 2010
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of cabozantinib in astrocytoma (4 arms), sponsored by Exelixis, Inc. Primary endpoints: Treatment Emergent Adverse Events at 13 months and Objective Response Rate at 13 months. Started Apr 2010; status: terminated.
02
Drugs
cabozantinib
03
Conditions
astrocytoma
Beyond the preview
Go deeper on NCT01068782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01068782.